

1 **The impact of laparoscopic ovarian drilling on AMH & ovarian reserve: a meta-analysis**

2 Saad A Amer¹, Tarek T El Shamy², Cathryn James², Ali H Yosef^{3,4}, Ahmed A. Mohamed,^{1,4}

3 ¹ Department of Obstetrics and Gynaecology, University of Nottingham, Royal Derby Hospital, Derby,
4 United Kingdom, DE22 3DT.

5 ² Derby Teaching Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, United Kingdom,
6 DE22 3DT.

7 ³ Department of Obstetrics and Gynaecology, The University of British Columbia, Vancouver, BC,
8 Canada, V6H3N1.

9 ⁴ Permanent address: Department of Obstetrics and Gynaecology, Assiut University, Assiut, Egypt.

10

11 ***Corresponding author:***

12 Saad A K S Amer, MD, FRCOG

13 Division of Medical Sciences & Graduate Entry Medicine

14 School of Medicine

15 University of Nottingham

16 Royal Derby Hospital Centre

17 Uttoxeter Road

18 Derby DE22 3DT United Kingdom

19 Email: saad.amer@nottingham.ac.uk

20 Tel: +447957567635

21 Office: +44 1332786773

22

23 ***Short title:*** Effect of ovarian drilling on ovarian reserve

24 **Abstract**

25 Laparoscopic ovarian drilling (LOD) has been widely utilised as an effective treatment in anovulatory
26 women with polycystic ovarian syndrome (PCOS). However, there has been a growing concern over a
27 possible damaging effect of this procedure on ovarian reserve. The objective of this study was to
28 investigate the hypothesis that LOD compromises ovarian reserve as measured by post-operative
29 changes in circulating anti-Müllerian hormone (AMH). This meta-analysis included all cohort studies
30 as well as randomised controlled trials investigating serum AMH concentrations and other ovarian
31 reserve markers in PCOS women undergoing LOD. Various databases were searched including
32 MEDLINE, EMBASE, Dynamed Plus, ScienceDirect, TRIP database, ClinicalTrials.gov and
33 Cochrane Library from January 2000 to December 2016. Sixty studies were identified, of which seven
34 were deemed eligible for this review. AMH data were extracted from each study and entered into
35 RevMan software to calculate the weighted mean difference (WMD) between pre- and post-operative
36 values. Pooled analysis of all studies (n=442) revealed a statistically significant decline in serum
37 AMH concentration after LOD (WMD -2.13ng/ml; 95% confidence interval (CI) -2.97 to -1.30).
38 Subgroup analysis based on duration of follow-up, AMH kit, laterality of surgery and amount of
39 energy applied during LOD consistently showed a statistically significant fall in serum AMH
40 concentration. In conclusion, although LOD seems to markedly reduce circulating AMH, it remains
41 uncertain whether this reflects a real damage to ovarian reserve or normalisation of the high
42 preoperative serum AMH levels. Further long-term studies on ovarian reserve after LOD are required
43 to address this uncertainty.

44

45

46 **Key words:** Anti-Müllerian hormone, Laparoscopic ovarian drilling, ovarian diathermy, ovarian
47 electrocautery, ovarian reserve, polycystic ovarian syndrome

48

49 **Introduction**

50 Polycystic ovarian syndrome (PCOS) is a very common ovarian endocrinopathy with a prevalence of
51 6-20% amongst women of reproductive age (Yildiz *et al.* 2012) and about 90% amongst women with
52 anovulatory or infertility (Hull 1987). It is characterized by a varied combination of clinical
53 (anovulation and hyperandrogenism), biochemical (excess serum luteinizing hormone and androgen
54 concentrations) and ovarian morphological (polycystic ovaries) features.

55 For PCOS women with anovulatory infertility, laparoscopic ovarian drilling (LOD) has been well-
56 established as a successful second line treatment for ovulation induction after failure of clomiphene
57 citrate (Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2008, Farquhar
58 *et al.* 2012). In addition to being as effective as gonadotrophin ovarian stimulation, LOD, offers
59 several advantages over this treatment such as avoiding ovarian hyperstimulation syndrome and
60 multiple pregnancies, reducing costs and negating the need for complex monitoring (Bayram *et al.*
61 2004, Farquhar *et al.* 2012). Furthermore, with LOD, a single treatment leads to repeated
62 physiological ovulatory cycles and potentially repeated pregnancies without the need for repeated
63 courses of medical treatment. Moreover, several follow-up studies provided evidence of long-term
64 reproductive and endocrinological benefits of LOD (Gjønnæss 1998, Amer *et al.* 2002, Nahuis *et al.*
65 2012). We have previously reported long-term improvement in menstrual cycles and reproductive
66 performance in about a third of PCOS women undergoing LOD for up to nine years (Amer *et al.*
67 2002). Similarly, Nahuis *et al.* (2012) followed PCOS women for up to 12 years after LOD reporting
68 high pregnancy rate (61% conception of a second child) with long-term improvement of menstrual
69 cycles in 44% of cases.

70 Despite its proven efficacy, there has been a growing concern over the possible damaging effect of
71 LOD on ovarian reserve. Our group and several other researchers have previously reported a
72 significant reduction in serum anti-Müllerian hormone after LOD (Weerakiet *et al.* 2007, Amer *et al.*
73 2009, Elmashad 2011, Farzadi *et al.* 2012, Syam *et al.* 2014, Sunj *et al.* 2014a, Rezk *et al.* 2016,
74 Giampaolino *et al.* 2016). However, given the relatively small numbers of patients included in these
75 studies, further evidence is required to allow a firm conclusion.

76 Anti-Müllerian hormone (AMH) is exclusively secreted by granulosa cells of growing follicles
77 including primary, pre-antral, small antral (4-6 mm) and to less extent larger antral follicles (7-9 mm)
78 (Weenen *et al.* 2004, Anderson *et al.* 2010). Thus, circulating AMH is now widely accepted as a
79 reliable marker for ovarian reserve (Coccia and Rizzello, 2008; Robertson, 2008; Andersen *et al.*
80 2010). Furthermore, serum AMH concentration is generally stable with minimal inter- and intra-cycle
81 fluctuations making it an ideal candidate for detecting small changes in ovarian reserve following
82 LOD (Lambert-Messerlian *et al.* 2016).

83 Based on the above, we have designed this systematic review and meta-analysis aiming to investigate
84 the impact of LOD on ovarian reserve as determined mainly by serum AMH levels.

85 **Materials and Methods:**

86 This meta-analysis was carried out according to the Preferred Reporting Items for Systematic Reviews
87 and Meta-analyses (PRISMA) guidelines (Liberati *et al.* 2009) and was registered in PROSPERO
88 (CRD42016039687).

89 **Inclusion criteria**

90 This meta-analysis included all published cohort studies as well as randomized controlled trials
91 (RCTs) that investigated changes in serum anti-Müllerian hormone (AMH) concentration in
92 anovulatory women with PCOS undergoing LOD.

93 **Outcome measures**

94 **Primary measure:**

95 This included postoperative changes in serum AMH concentration.

96 **Secondary measures:**

97 These included postoperative changes in serum follicle stimulating hormone (FSH) concentration and
98 antral follicle count (AFC) on ultrasound scan.

99 **Search strategy**

100 A detailed electronic search was conducted using numerous databases from January 2000 to June

101 2016 to identify studies investigating the effect of laparoscopic ovarian drilling on circulating AMH
102 levels and other markers of ovarian reserve. Databases included MEDLINE (31 studies), Embase (29
103 studies), Dynamed (0), ScienceDirect (0), TRIP database (0), ClinicalTrials.gov (0) and the Cochrane
104 Library (0). Medical Subject Headings (MeSH) terms used included: laparoscopy, polycystic ovary
105 syndrome, ovarian drilling, ovarian diathermy, ovarian electrocautery, ovarian reserve, anti-Müllerian
106 hormone and antral follicle count. Search was limited to the English Language, adult Females of
107 reproductive age. Three co-authors (AM, TE and AY) conducted the searches and then an accredited
108 clinical librarian (CJ) independently repeated the search using the same criteria. All identified articles
109 were retrieved, and their reference lists were manually checked for further relevant studies. Published
110 conference abstracts, which could be identified from ScienceDirect database, were also considered for
111 the analysis.

112 **Study selection**

113 Three investigators (AM, TE and AY) independently screened the title and abstract of all identified
114 articles to assess relevance to our meta-analysis. In case of disagreement, the full text was retrieved
115 and reviewed independently by a senior author (SA) for a final decision.

116 All identified articles were evaluated according to a standardized format including study design,
117 methods, participant characteristics, intervention, and results. Three investigators scored the studies
118 and collected the information independently (AM, TE, AY). In case of discrepancies in scoring
119 between the three investigators, a consensus was reached after discussion or after involvement of the
120 senior investigator (SA).

121 In two studies, the mean \pm SD of serum AMH was missing as data were presented as median and range
122 (Amer *et al.* 2009, Sunj *et al.* 2014a). The mean \pm SD was also missing for AFC in two studies
123 (Farzadi *et al.* 2012, Sunj *et al.* 2014a) and for FSH in four studies (Weerakiet *et al.* 2007, Sunj *et al.*
124 2014a, Giampaolino, et al, 2016, Rezk *et al.* 2016.). We obtained the mean \pm SD of serum AMH and
125 FSH levels from the original data of our previous study (Amer *et al.* 2009). Authors of the other
126 studies were contacted and three (Sunj *et al.* 2014, Giampaolino *et al.* 2016, Rezk *et al.* 2016)
127 responded providing the missing data.

128 **Quality of included studies and risk of bias assessment**

129 Modified Newcastle-Ottawa scale was utilised for assessing the quality and risk of bias of the
130 included studies (Raffi *et al.* 2012, Mohamed *et al.* 2016). Each article was scored according to three
131 categories including selection (maximum three stars), comparability (four stars), and outcomes (two
132 stars). Selection was rated according to recruitment bias, selection of consecutive patients and power
133 calculation. Comparability was assessed based on adjustment of analysis for four confounders
134 including patients' age (<40), baseline serum AMH, laterality of surgery and number of punctures
135 according to estimated ovarian volume, type of instrument and energy used. Outcome was scored
136 according to completeness of at least three-month follow-up after surgery. In the current analysis, we
137 have given more weight to comparability factors and used the cut-off level of six stars with a
138 minimum of three stars in the comparability category (Raffi *et al.* 2012, Mohamed *et al.* 2016). Table
139 1 shows the results of quality scores of the studies included in this analysis.

140 **Data extraction and analysis**

141 Pre- and post-operative mean \pm SD serum AMH (ng/ml) and FSH (mIU/ml) concentrations and AFC
142 were extracted from the individual articles and entered into RevMan software (Review Manager,
143 version 5.1, The Cochrane Collaboration, 2011; The Nordic Cochrane Centre, Copenhagen, Denmark)
144 for meta-analysis. The weighted mean difference (WMD) between pre- and post-operative values was
145 calculated. Statistical heterogeneity between studies was assessed by *I*-squared (I^2) statistics and
146 values of $\geq 50\%$ were indicative of high heterogeneity (Higgins *et al.* 2003). When heterogeneity was
147 significant, a random-effect model was used for meta-analysis. Fixed effect meta-analysis was used
148 when there was no significant heterogeneity.

149 Overall analysis of data from all studies was first performed, irrespective of duration of the follow up,
150 laterality of surgery and type of AMH assay kit used. In studies with multiple measurements at
151 different post-operative follow up points, the latest AMH measurement was used for the overall
152 analysis. In order to account for confounding factors, subgroup analyses were performed based on
153 duration of follow-up, AMH kits used, laterality (bilateral and unilateral) of LOD and amount of
154 energy applied during LOD. No sensitivity analysis was performed as all the studies scored high on
155 the Modified Newcastle-Ottawa scale indicating low risk of bias (Table 1).

156 Results

157 The electronic database search identified 60 studies. All articles were screened and relevant articles
158 were fully reviewed for eligibility for the study objectives and inclusion criteria. As a result, seven
159 articles were deemed eligible for this meta-analysis (Fig.1).

160 Excluded studies

161 Of the 60 identified articles, fifty-one did not use the anti-Müllerian hormone as a marker of ovarian
162 reserve and were therefore excluded from this meta-analysis. Two further studies were excluded, one
163 due to lack of preoperative serum AMH levels (postoperative AMH levels were compared with a
164 control group) (Weerakiet *et al.* 2007), and the other one (Sunj *et al.* 2014b) due to duplication of
165 another study (Sunj *et al.* 2014a), which is included in the meta-analysis.

166 Included studies

167 Details of the seven studies are shown in table 2.

168 Study design

169 This systematic review included five cohort studies (Amer *et al.* 2009, Elmashad 2011, Farzadi *et*
170 *al.* 2012, Seyam *et al.* 2014, Sunj *et al.* 2014a) and two RCTs (Giampaolino *et al.* 2016, Rezk *et*
171 *al.* 2016). The RCT by Rezk *et al.* (2016) compared unilateral versus bilateral LOD. The two arms of
172 this RCT were combined and used as a cohort study in the overall analysis, and then each arm was
173 included separately in subgroup analysis. The other RCT compared laparoscopic versus transvaginal
174 hydro-laparoscopic ovarian drilling (TH-LOD) (Giampaolino *et al.* 2016). Only the LOD group of this
175 RCT was included as a cohort study in the current meta-analysis (Giampaolino *et al.* 2016).

176 Participants

177 All studies used appropriate selection criteria and all participants underwent the same surgical
178 techniques of LOD. Inclusion and exclusion criteria were appropriately reported in all studies. All
179 patients were accounted for in all studies.

180 PCOS diagnosis

181 All seven studies included in this meta-analysis utilised Rotterdam criteria for the diagnosis of PCOS

182 (Amer *et al.* 2009, Elmashad 2011, Farzadi *et al.* 2012, Seyam *et al.* 2014, Sunj *et al.* 2014a, Rezk *et*
183 *al.* 2016, Giampaolino *et al.* 2016).

184 **Laparoscopic ovarian drilling**

185 Laparoscopic ovarian drilling (LOD) was performed using monopolar diathermy needle in six studies
186 (Amer *et al.* 2009, Elmashad 2011, Seyam *et al.* 2014, Sunj *et al.* 2014a, Rezk *et al.* 2016,
187 Giampaolino *et al.* 2016). The remaining study used monopolar hook diathermy for LOD (Farzadi *et*
188 *al.* 2012). One study randomised patients to undergo either LOD or TH-LOD, but only the LOD arm
189 was included in the meta-analysis (Giampaolino *et al.* 2016).

190 With regards to the number of punctures and amount of energy delivered to the ovary during LOD,
191 two studies reported four punctures per ovary at a power setting of 30W applied for 5 seconds per
192 puncture i.e. 450 joules (J) per ovary (Amer *et al.* 2009, Elmashad 2011). In the two studies
193 comparing bilateral versus unilateral LOD, the authors applied 600 J per ovary (5 punctures x 4s x
194 30W) in the bilateral group and 60 J per 1cm³ of ovarian volume in the unilateral group (delivered as
195 30W for 4s per puncture), which is equivalent to 627 J applied to a 10cm³ ovary (Sunj *et al.* 2014a,
196 Rezk *et al.* 2016). Seyam and co-workers reported 4-6 punctures per ovary at a power of 30 W for 4-5
197 seconds per puncture i.e. 480 – 900 J per ovary (Seyam *et al.* 2014). Giampaolino *et al.* (2016)
198 applied 3-6 punctures per ovary using 40 W for 4-5 seconds per puncture i.e. 480-1200 J per ovary.
199 One study reported six to seven punctures per ovary, but no details were provided regarding the power
200 setting or the duration of each puncture (Farzadi *et al.* 2012).

201 Concerning laterality, five studies reported that LOD was carried out bilaterally (Amer *et al.* 2009,
202 Elmashad 2011, Farzadi *et al.* 2012, Seyam *et al.* 2014, Giampaolino *et al.* 2016). The remaining two
203 studies compared unilateral versus bilateral LOD (Sunj *et al.* 2014a, Rezk *et al.* 2016).

204 **Length of follow up after LOD**

205 Six studies completed six-month follow-up after LOD, (Amer *et al.* 2009, Farzadi *et al.* 2012,
206 Seyam *et al.* 2014, Sunj *et al.* 2014a, Rezk *et al.* 2016, Giampaolino *et al.* 2016) whilst the
207 remaining study followed participants for three months (Elmashad 2011). Four studies carried out
208 multiple measurements within one month (Amer *et al.* 2009, Farzadi *et al.* 2012, Seyam *et al.*

209 2014, Sunj *et al.* 2014a) and three months (Table 2) (Amer *et al.* 2009, Farzadi *et al.* 2012,
210 Seyam *et al.* 2014, Rezk *et al.* 2016).

211 **AMH kits**

212 Four AMH kits were used in different studies (Table 2). Immunotech (IOT) AMH enzyme
213 immunoassay kit (Immunotech, Beckman Coulter, Marseille, France) was used in Four studies (Amer
214 *et al.* 2009, Elmashad 2011, Rezk *et al.* 2016; Seyam *et al.* 2014). The intra- and inter-assay
215 coefficients of variation for this AMH assay are below 12.3% and 14.2%, respectively, with a
216 detection limit of 0.14ng/ml. The modified AMH Gen II enzyme linked immunosorbent assay
217 (ELISA) (Beckman Coulter, Chaska, MN, USA) was used by one study (Sunj *et al.* 2014a). The
218 intra and inter-assay coefficients of variation for this AMH kit are both below 10%, with a detection
219 limit of 0.08ng/ml. Farzadi *et al.* (2012) used AMH enzyme immunoassay (EIA) kit (ELAab &
220 USCNLIFE, Wuhan ELAab Science Co.Ltd). The lowest detection limit of this assay is 0.053ng/ml
221 according to instructions provided in the analysis kit.¹¹ The last study used DSL active AMH ELISA
222 kit (Diagnostic Systems Laboratories, Webster TX). The intra-assay and interassay coefficients of
223 variation for this kit were 4.6% and 8.0%, respectively, with a detection limit of 0.017ng/ml
224 (Giampaolino *et al.* 2016).

225 **Antral follicle count**

226 Four studies reported the AFC as an outcome measure of ovarian reserve (Elmashad 2011, Farzadi *et*
227 *al.* 2012, Rezk *et al.* 2016, Seyam *et al.* 2014). The authors of another study provided the AFC
228 data, which were missing from the published article, in response to our communication (Sunj
229 *et al.* 2014a). Elmashad (2011) defined AFC as the number of follicles measuring 2–9 mm in
230 diameter. Seyam and co-workers (2014) defined AFC as the count of all follicles measuring
231 2-10 mm in diameter. The remaining three studies did not define the size of the follicles used
232 for the AFC, but reported using the Rotterdam definition of polycystic ovaries (>12 follicles
233 measuring 2-9 mm) (Farzadi *et al.* 2012, Rezk *et al.* 2016, Sunj *et al.* 2014a).

234 **Potential source of bias**

235 In all seven studies, selection methods were clearly described and recruitment followed a consecutive
236 fashion. This made it possible to assess selection bias in all studies.

237 ***Pooled results***

238 ***Overall results***

239 Table 3 shows mean±SD serum AMH concentrations before and after LOD in all seven
240 studies. Pooled analysis of all seven studies including 442 participants revealed a statistically
241 significant decline of serum AMH concentration after LOD (WMD -2.13ng/ml; 95%
242 confidence interval (CI) -2.97 to -1.30). Heterogeneity between studies was high ($I^2 = 87\%$)
243 (Fig. 2) (Amer *et al.* 2009, Elmashad 2011, Farzadi *et al.* 2012, Seyam *et al.* 2014, Sunj *et al.* 2014a,
244 Giampaolino *et al.* 2016, Rezk *et al.* 2016).

245 ***Subgroup analysis***

246 ***Studies using different AMH assays***

247 Pooled results of four studies (n=197) using IOT AMH kit showing a statistically significant drop in
248 serum AMH concentration (WMD -2.80; 95% CI -3.22 to -2.38; $I^2=0\%$) with low heterogeneity
249 between studies (Amer *et al.* 2009, Elmashad 2011, Seyam *et al.* 2014, Rezk *et al.* 2016). Each of the
250 other three AMH assays (Modified Gen II, DSL and Abbott Diagnostic kits) was used by one study
251 and meta-analysis was therefore not possible (Farzadi *et al.* 2012, Sunj *et al.* 2014a, Giampaolino *et*
252 *al.* 2016).

253 ***Studies with different length of follow-up***

254 Analysis of four studies including 195 patients revealed a statistically significant decline in serum
255 AMH concentration one month after LOD (WMD -2.11; 95% CI -2.62 to -1.59; $I^2= 17\%$) (Amer *et al.*
256 2009, Farzadi *et al.* 2012, Seyam *et al.* 2014, Sunj *et al.* 2014a). Similarly, analysis of data from five
257 studies (n=277) with a three-month follow-up showed a statistically significant fall in serum AMH
258 concentration after surgery (WMD, -2.74; 95% CI -3.16 to -2.33; $I^2=0\%$) (Amer *et al.* 2009, Elmashad
259 2011, Farzadi *et al.* 2012, Seyam *et al.* 2014, Rezk *et al.* 2016). Analysis of six studies (n=419)
260 showed a statistically significant decline in serum AMH concentration six months after LOD (WMD,

261 -2.03; 95% CI -2.90 to -1.16; $I^2= 88\%$) (Amer *et al.* 2009, Farzadi *et al.* 2012, Seyam *et al.* 2014,
262 Sunj *et al.* 2014a, Giampaolino *et al.* 2016, Rezk *et al.* 2016).

263 ***Laterality of LOD***

264 Bilateral LOD was performed in seven studies including 341 patients (Amer *et al.* 2009, Elmashad
265 2011, Farzadi *et al.* 2012, Seyam *et al.* 2014, Sunj *et al.* 2014a, Giampaolino *et al.* 2016, Rezk *et al.*
266 2016). Pooled analysis of these studies revealed a statistically significant drop in circulating serum
267 AMH (WMD -2.31; 95% CI -3.29 to -1.33; $I^2= 87\%$). Analysis of two studies (n=101) measuring
268 serum AMH changes after unilateral LOD showed a statistically significant decline in postoperative
269 serum AMH concentration (WMD -1.59; 95% CI -2.69 to -0.49; $I^2= 69\%$) (Sunj *et al.* 2014a, Rezk *et*
270 *al.* 2016).

271 ***Sub-analysis According to energy delivered to ovaries during LOD***

272 Four studies including 253 patients used up to 600 J in ovarian drilling. Pooled analysis of these
273 studies revealed a statistically significant drop in postoperative serum AMH levels (WMD -2.45; 95%
274 CI -3.41 to -1.48; $I^2= 72\%$) (Amer *et al.* 2009, Elmashad 2011, Sunj *et al.* 2014a, Rezk *et al.* 2016).
275 Two studies with 159 patients were identified using up to 900-1200 J in ovarian drilling. Pooled
276 analysis of the results showed a statistically significant decline in postoperative serum AMH
277 concentrations (WMD -1.93; 95% CI -3.72 to -0.14; $I^2= 94\%$) (Seyam *et al.* 2014, Giampaolino *et*
278 *al.*,2016).

279 ***Secondary outcomes:***

280 Table 4 shows serum FSH concentrations before and after LOD in six studies (n=412). Pooled
281 analysis of these studies revealed no change in circulating FSH (WMD 0.03; 95% CI -0.46 to 0.52;
282 $I^2= 90\%$) (Amer *et al.* 2009, Elmashad 2011, Seyam *et al.* 2014, Sunj *et al.* 2014a, Giampaolino *et al.*
283 2016, Rezk *et al.* 2016).

284 Five studies measured post-LOD changes in AFC, of which one was excluded due to lacking
285 postoperative mean±SD AFC (Farzadi *et al.* 2012). Table 5 shows AFC results of the included four
286 studies. Pooled data of these studies showed no significant change in AFC (WMD -3.46; 95% CI -
287 10.73 to 3.81; $I^2= 99\%$) (Elmashad 2011, Seyam *et al.* 2014, Sunj *et al.* 2014a, Rezk *et al.* 2016).

288 Further analysis was carried out to AFC follow-up within three and six months. Follow-up within
289 three months were carried out with four studies including 264 patients. Pooled analysis of the results
290 showed no significant changes in AFC after surgery (WMD -5.51; 95% CI -11.20 to 0.19; $I^2= 99\%$)
291 (Elmashad 2011, Seyam *et al.* 2014, Sunj *et al.* 2014a, Rezk *et al.* 2016). Three studies with 241
292 patients were identified performing follow-up assessment of AFC at six months. Pooled analysis of
293 these studies revealed no significant change to AFC postoperative (WMD 0.04; 95% CI -5.52 to 5.59;
294 $I^2= 98\%$) (Seyam *et al.* 2014, Sunj *et al.* 2014a, Rezk *et al.* 2016).

295 **Discussion**

296 This is the first systematic review and meta-analysis to investigate the impact of LOD on ovarian
297 reserve as determined by changes in postoperative serum AMH concentration. The overall analysis
298 revealed a marked decline of 2.13 ng/ml, which represents 43% of the cut-off level of serum AMH
299 concentration (4.9ng/ml) in women with PCOS (Dewailly *et al.* 2011). This decline in circulating
300 AMH seems to be sustained for up to six months after LOD. Further subgroup analysis taking into
301 account all possible confounding factors consistently showed a significant decline in postoperative
302 serum AMH. The sub-analysis including studies with one- and three-month follow-up and studies
303 using IOT AMH kit revealed low heterogeneity. This suggests that the high heterogeneity between
304 studies seems to be due to variation in the follow-up periods and in the AMH assay kits used.

305 The exact mechanism of the post-LOD fall in circulating AMH remains uncertain. A possible
306 explanation could be a decrease in AMH synthesis due to loss of the primary, pre-antral and small
307 antral follicles, which are the main source of AMH, as a result of thermal damage during LOD
308 (Weenen *et al.* 2004, Anderson *et al.* 2010). This hypothesis is further supported by the preliminary
309 finding of an obvious trend towards a decline in AFC after LOD, although this did not reach statistical
310 significance, possibly due to the small numbers involved in that analysis and the high heterogeneity.
311 Furthermore, we have recently reported a similar decline of circulating AMH following ovarian
312 cystectomy (Raffi *et al.* 2012, Mohamed *et al.* 2016). This suggests that any surgical trauma to the
313 ovary is associated with loss of ovarian follicles with subsequent reduction in AMH production.
314 Whether this effect on AFC and AMH is temporary with subsequent recovery remains to be
315 investigated with further long term studies. Interestingly, two studies, which are included in this meta-

316 analysis, reported a significant postoperative decline of AFC, which was sustained for up to six
317 months in one study (Seyam *et al.* 2014), but seemed to have recovered at six-month follow-up in the
318 other study (Rezk *et al.* 2016). These conflicting data may explain the outcome of the pooled
319 analysis, which revealed no significant change in AFC at six-month follow-up. Further adequately
320 designed short, medium and long-term cohort studies are required to address this issue.

321 It is interesting to see that even unilateral ovarian drilling caused a significant decline in circulating
322 AMH, refuting the hypothesis that unilateral treatment could be less damaging to the ovarian reserve.
323 It is worth mentioning that ovulation and pregnancy rates were higher in women undergoing bilateral
324 versus unilateral ovarian drilling (Rezk *et al.* 2016). It is therefore possible to conclude that limiting
325 the drilling to one ovary may compromise the success rates without any significant benefits to ovarian
326 reserve. It was also interesting to see that despite the wide variation of the amount of energy used in
327 different studies ranging between 450 and 1200 J per ovary, the decline in circulating AMH was more
328 or less similar in all studies. This suggests that the range of energy doses utilised in these studies seem
329 to be relatively safe to ovarian function with no excessive tissue damage with the higher doses.

330 One of the two RCTs in this meta-analysis compared AMH changes after LOD *vs.* transvaginal hydro-
331 laparoscopic ovarian drilling (TH-LOD) (Giampaolino *et al.* 2016). In order to minimise heterogeneity
332 between studies we decided to exclude the group undergoing TH-LOD due to the significant
333 differences in techniques between this approach and the standard LOD used in all included studies.
334 Whilst TH-LOD utilises bipolar diathermy, LOD on the other hand uses monopolar diathermy.
335 Interestingly, there was no difference in the AMH changes after TH-LOD (Preoperative AMH,
336 5.84 ± 1.16 *vs.* postoperative, 4.83 ± 1.10 ng/l, $p < 0.0001$) compared to LOD (6.06 ± 1.18 *vs.* 5.00 ± 1.29
337 ng/l, $p < 0.0001$) (Giampaolino *et al.* 2016). This suggests that the degree of ovarian tissue damage is
338 similar between the two energy modalities. This is surprising as bipolar diathermy is believed to
339 reduce the risk of excessive ovarian tissue necrosis compared to monopolar energy.

340 It is well-known that serum AMH levels are generally stable with minimal inter- and intra-cycle
341 variations and with a very gradual decline (5.6% per year) with advancing age (Api 2009). We
342 therefore believe that a 43% decline in AMH level after LOD is a marked drop. However, it is still
343 uncertain whether this reflects a real decline in ovarian reserve or merely reflects normalization of the

344 high preoperative serum AMH levels, which is a characteristic feature of PCOS (Amer *et al.* 2004).
345 The well-established high pregnancy rates as well as the well-documented positive long-term
346 reproductive effects of LOD favours the AMH normalisation hypothesis (Amer *et al.* 2002, Gjønness
347 1998, Api 2009). This is further supported by the lack of any effect of LOD on circulating FSH.
348 However, further long-term studies of ovarian reserve after LOD are required to support one of the
349 above two hypotheses. Based on our findings and until further long-term data become available,
350 clinicians could continue to offer LOD to their PCOS patients after carefully weighing the well-
351 known benefits against the potential risks to ovarian reserve.

352 The main limitation of this review is the high heterogeneity between studies, possibly due to the
353 variation in the AMH assay and amount of energy delivered to the ovary during LOD. Although, all
354 studies used similar techniques of LOD, there were differences in the amount of energy delivered to
355 the ovary with some studies applying 450 - 600J per ovary (Amer *et al.*, 2009; Elmashad, 2011; Rezk
356 *et al.*, 2016; Seyam *et al.*, 2014) whilst others delivering up to 900 J (Seyam *et al.* 2014) and 1200 J
357 (Giampaolino *et al.* 2016) per ovary.

358 In conclusion, LOD significantly lowers circulating AMH, but this may not necessarily reflect a real
359 damage to ovarian reserve. Given its proven efficacy and its long-term benefits, LOD should remain
360 as an option in the management of anovulatory PCOS patients.

361

362 **Declaration of interest**

363 The authors report no conflict of interest

364 **Funding**

365 This work was supported by the Egyptian Cultural Centre and Education bureau in London and the British Council in
366 Cairo.

367 **Acknowledgment**

368 The authors are grateful to the funders including the Egyptian Cultural Centre and Education bureau
369 in London and the British Council in Cairo for supporting this work

370

371

372

373 **References**

- 374 **Amer SA, Gopalan V, Li TC, Ledger WL & Cooke ID** 2002 Long term follow-up of patients
375 with polycystic ovarian syndrome after laparoscopic ovarian drilling: clinical outcome. *Human*
376 *Reproduction* **17** 2035–2042.
- 377 **Amer SA, Li TC & Ledger WL** 2004 Ovulation induction using laparoscopic ovarian drilling in
378 women with polycystic ovarian syndrome: predictors of success. *Human Reproduction* 2004 **19**
379 1719–1724.
- 380 **Amer SA, Li TC & Ledger WL** 2009 The value of measuring anti-Müllerian hormone in women
381 with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy. *Human*
382 *Reproduction* **24** 2760–2766.
- 383 **Api M** 2009 Is ovarian reserve diminished after laparoscopic ovarian drilling? *Gynecological*
384 *Endocrinology* **25** 159–165.
- 385 **Andersen CY, Schmidt KT, Kristensen SG, Rosendahl M, Byskov AG, Ernst E** 2010
386 Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small
387 antral follicles. *Human Reproduction* **25** 1282–1287.
- 388 **Bayram N, Van Wely M, Kaaijk EM, Bossuyt PM & van der Veen F** 2004 Using an
389 electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in
390 polycystic ovary syndrome: randomised controlled trial. *British Medical Journal* **328** 192.
- 391 **Coccia ME, Rizzello F. Ovarian reserve** 2008 *Annals of the New York Academy of Sciences*.
392 **1127** 27–30.
- 393 **Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A & Catteau-**
394 **Jonard S** 2011 Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values
395 of follicle count on ultrasound and of the serum AMH level for the definition of polycystic
396 ovaries. *Human Reproduction* **26** 3123–3129.
- 397 **Elmashad AI** 2011 Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and
398 ovarian stromal blood flow using three-dimensional power Doppler in women with anovulatory
399 polycystic ovary syndrome. *Fertility Sterility* **95** 2342–2346.

- 400 **Farquhar C, Brown J & Marjoribanks J** 2012 Laparoscopic drilling by diathermy or laser for
401 ovulation induction in anovulatory polycystic ovary syndrome. *The Cochrane Library*
402 **13**:CD001122.
- 403 **Farzadi L, Nouri M, Ghojzadeh M, Mohiti M & Aghadavod E** 2012 Evaluation of ovarian
404 reserve after laparoscopic surgery in patients with polycystic ovary syndrome. *Bioimpacts* **2** 167–
405 170.
- 406 **Giampaolino P, Morra I, Della Corte L, Sparice S, Di Carlo C, Nappi C & Bifulco G** 2016
407 Serum anti-Mullerian hormone levels after ovarian drilling for the second-line treatment of
408 polycystic ovary syndrome: a pilot-randomized study comparing laparoscopy and transvaginal
409 hydrolaparoscopy. *Gynecological Endocrinology* **24** 1–4.
- 410 **Gjønnæss H** 1998 Late endocrine effects of ovarian electrocautery in women with polycystic
411 ovary syndrome. *Fertility Sterility* **69** 697–701.
- 412 **Higgins JP, Thompson SG, Deeks JJ & Altman DG** 2003 Measuring inconsistency in meta-
413 analyses. *British Medical Journal* **327** 557–560.
- 414 **Hull MG** 1987 Epidemiology of infertility and polycystic ovarian disease: endocrinological and
415 demographic studies. *Gynecological Endocrinology* **1** 235–245.
- 416 **Lambert-Messerlian G, Plante B, Eklund EE, Raker C & Moore RG** 2016 Levels of
417 antimüllerian hormone in serum during the normal menstrual cycle. *Fertility Sterility* **105** 208–
418 213.
- 419 **Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M,**
420 **Devereaux PJ, Kleijnen J & Moher D** 2009 The PRISMA statement for reporting systematic
421 reviews and meta-analyses of studies that evaluate health care interventions: explanation and
422 elaboration. *Annals of Internal Medicine* **151** W65-94.
- 423 **Mohamed AA, Al-Hussaini TK, Fathalla MM, El Shamy TT, Abdelaal II & Amer SA** 2016
424 The Impact of excision of Benign Non-Endometriotic Ovarian Cysts on Ovarian Reserve: A
425 systematic review. *American Journal Obstetrics and Gynecology* **215** 169–176.
- 426 **Nahuis MJ, Oude Lohuis E, Kose N, Bayram N, Hompes P, Oosterhuis GJ, Kaaijk EM,**
427 **Cohlen BJ, Bossuyt PP, van der Veen F et al.** 2012 Long-term follow-up of laparoscopic

- 428 electrocautery of the ovaries versus ovulation induction with recombinant FSH in clomiphene
 429 citrate-resistant women with polycystic ovary syndrome: an economic evaluation. *Human*
 430 *Reproduction* **27** 3577–3582.
- 431 **Raffi F, Metwally M & Amer S.** 2012 The impact of excision of ovarian endometrioma on
 432 ovarian reserve: a systematic review and meta-analysis. *Journal of Clinical Endocrinology and*
 433 *Metabolism* **97** 3146–3154.
- 434 **Rezk M, Sayyed T & Saleh S** 2016 Impact of unilateral versus bilateral laparoscopic ovarian
 435 drilling on ovarian reserve and pregnancy rate: a randomized clinical trial. *Gynecological*
 436 *Endocrinology* **32** 399–402.
- 437 **Robertson DM** 2008 Anti-Müllerian hormone as a marker of ovarian reserve: an update.
 438 *Womens Health* **4** 137–141.
- 439 **Seyam EM, Mohamed TG, Hasan MM & Al Mawgood MH** 2014 Evaluation of
 440 ultrasonographic and Anti-Müllerian Hormone (AMH) changes as predictors for ovarian reserve
 441 after laparoscopic ovarian drilling for women with polycystic ovarian syndrome. *Middle East*
 442 *Fertility Society Journal* **19** 314–323.
- 443 **Sunj M, Canic T, Jeroncic A, Karelavic D, Tandara M, Juric S & Palada I** 2014a Anti-
 444 Müllerian hormone, testosterone and free androgen index following the dose-adjusted unilateral
 445 diathermy in women with polycystic ovary syndrome. *European Journal Obstetrics Gynecology*
 446 *and Reproductive Biology* **179** 163–169.
- 447 **Sunj M, Kasum M, Canic T, Karelavic D, Tandara M, Tandara L & Palada I** 2014b
 448 Assessment of ovarian reserve after unilateral diathermy with thermal doses adjusted to ovarian
 449 volume. *Gynecological Endocrinology* **30** 785–788.
- 450 **Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group** 2008
 451 Consensus on infertility treatment related to polycystic ovary syndrome. *Fertility Sterility* **89** 505–
 452 522.
- 453 **Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P,**
 454 **Fauser BC, Themmen AP** 2004 Anti-Müllerian hormone expression pattern in the human

455 ovary: potential implications for initial and cyclic follicle recruitment. *Molecular Human*
456 *Reproduction* **10** 77–83.

457 **Weerakiet S, Lertvikool S, Tingthanatikul Y, Wansumrith S, Leelaphiwat S & Jultanas R**
458 2007 Ovarian reserve in women with polycystic ovary syndrome who underwent laparoscopic
459 ovarian drilling. *Gynecological Endocrinology* **23** 455–460.

460 **Yildiz BO, Bozdog G, Yapici Z, Esinler I & Yarali H** 2012 Prevalence, phenotype and
461 cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. *Human*
462 *Reproduction* **27** 3067–3073.

463

464

Figure legends

Figure 1. PRISMA Flow Chart of the study selection process

Figure 2. WMD in serum AMH concentrations after laparoscopic ovarian drilling: pooled results for all seven studies

Abbreviations: AMH, anti-Müllerian hormone; CI, confidence interval; WMD, weighted mean difference.




Figure 1. PRISMA Flow Chart of the study selection process

195x180mm (72 x 72 DPI)




Figure 2. WMD in serum AMH concentrations after laparoscopic ovarian drilling: pooled results for all seven studies

Abbreviations: AMH, anti-Müllerian hormone; CI, confidence interval; WMD, weighted mean difference.

1764x428mm (96 x 96 DPI)

Table 1 Modified Newcastle Ottawa scale for risk of bias and quality assessment of the included studies

Author	Year	Selection (***)	Comparability (****)	Outcome (**)	Overall
Amer <i>et al.</i>	2009	**	****	**	8
Elmashad	2011	*	****	**	7
Farzadi <i>et al.</i>	2012	**	***	**	7
Seyam <i>et al.</i>	2014	**	****	**	8
Sunj <i>et al.</i>	2014a	**	****	**	8
Giampaolino <i>et al.</i>	2016	**	***	**	7
Rezk <i>et al.</i>	2016	**	****	**	8

Table 2 Characteristics of the seven studies included in the meta-analysis

Authors & year	country	Design	n	Age (years) mean±SD	Laterality	Energy per ovary (J)	FU Months	AMH assay	Secondary Outcomes
Amer <i>et al.</i> 2009	UK	Prospective cohort	29	28.4±0.9	Bilateral	450	6	IOT	FSH
Elmashad 2011	Kuwait	Prospective cohort	23	28.8±3.1	Bilateral	450	3	IOT	FSH, OV, AFC
Farzadi <i>et al.</i> 2012	Iran	Prospective cohort	30	28.4±2.3	Bilateral	***	6	EIA	AFC
Seyam <i>et al.</i> 2014	Egypt	Prospective cohort	40	31.6±4.5	Bilateral	480-900	6	IOT	FSH, AFC
Sunj <i>et al.</i> 2014a	Croatia	Prospective cohort	96	29.3±3.3 29.3±3.1	Unilateral=49 Bilateral=47	600 ~627¶	6	Gen II	FSH, AFC, OV
Giampaolino <i>et al.</i> 2016	Italy	RCT*	119	18-40**	Bilateral	480-1200	6	DSL	FSH
Rezk <i>et al.</i> 2016	Egypt	RCT	105	29.7±1.5 29.8±1.4	Unilateral=52 Bilateral=53	600 ~627¶	6	IOT	AFC, FSH

* RCT Arm 1, laparoscopy included in the study; Arm 2, laparotomy excluded

** age range of participants, SD not available

*** 6-7 punctures per ovary, but no data provided on energy

¶ energy delivered as 60 J per 1cm³ of ovarian volume, which is equivalent to 627 J per a 10cm³ ovary

Abbreviation: **RCT**, randomised controlled trial; **FU**, follow up; **J**, Joules; **OV**, ovarian volume; **IOT**, Immunotech AMH enzyme immunoassay; **EIA**, enzyme immunoassay (ELAab & USCNLIFE); **DSL**, Diagnostic System Laboratories ELISA AMH kit

Table 3 Pre- and Post-operative serum AMH concentrations in all analysed studies

Reference	n	Laterality	Serum AMH (ng/ml), mean±SD			
			Preoperative	Postoperative (1 month)	Postoperative (3 month)	Postoperative (6 month)
Amer <i>et al.</i> 2009	29	Bilateral	7.19 ± 5.0	6.75 ± 5.70	5.33 ± 3.90	3.68 ± 2.50
Elmashad 2011	23	Bilateral	7.40 ± 4.60	—	4.20 ± 2.50	—
Farzadi <i>et al.</i> 2012	30	Bilateral	8.40 ± 4.70	7.50 ± 4.50	7.00 ± 4.50	7.70 ± 4.40
Seyam <i>et al.</i> 2014	40	Bilateral	5.99 ± 2.30	3.40 ± 1.70	3.20 ± 1.70	3.10 ± 1.50
Sunj <i>et al.</i> 2014a	49	Unilateral	6.67 ± 2.89	5.02 ± 2.05	—	5.70 ± 2.05
	47	Bilateral	7.42 ± 2.78	4.98 ± 1.68	—	5.60 ± 1.70
	96	Overall	7.03 ± 2.85	5.00 ± 1.80	—	5.60 ± 1.80
Giampaolino <i>et al.</i> 2016	119	Bilateral	6.06 ± 1.18	—	—	5.00 ± 1.29
Rezk <i>et al.</i> 2016	52	Unilateral	8.60 ± 2.30	—	6.40 ± 1.20	6.50 ± 1.30
	53	Bilateral	8.70 ± 2.40	—	5.20 ± 1.30	5.50 ± 1.10
	105	Overall	8.60 ± 2.30	—	5.79 ± 1.30	5.90 ± 1.30

Table 4 Pre- and Post-operative serum FSH concentrations in all analysed studies.

Reference	n	Laterality	Serum FSH (IU/L), mean±S.D.			
			Preoperative	Postoperative (1 month)	Postoperative (3 month)	Postoperative (6 month)
Amer <i>et al.</i> 2009	29	Bilateral	5.3 ± 1.4	4.9±1.6	—	—
Elmashad 2011	23	Bilateral	4.9 ± 1.6	—	4.1 ± 1.4	—
Seyam <i>et al.</i> 2014	40	Bilateral	5.4 ± 2.7	5.7 ± 2.3	5.5 ± 2.1	5.45 ± 2.4
Sunj <i>et al.</i> 2014a	49	Unilateral	—	—	—	—
	47	Bilateral	—	—	—	—
	96	Overall	5.2 ± 1.17	5.7 ± 1.2	—	6.1 ± 1.2
Rezk <i>et al.</i> 2016	52	Unilateral	5.3 ± 1.4	—	5.41 ± 1.3	5.26 ± 1.4
	53	Bilateral	5.5 ± 1.2	—	5.52 ± 1.3	5.49 ± 1.3
	105	Overall	5.4 ± 1.3	—	—	5.3 ± 1.3

Table 5 Pre- and Post-operative antral follicle count (AFC) in all analysed studies.

Reference	n	Laterality	AFC, mean±S.D.			
			Preoperative	Postoperative (1 month)	Postoperative (3 month)	Postoperative (6 month)
Elmashad 2011	23	Bilateral	29.0 ± 2.4	—	15.0 ± 2.2	—
Seyam <i>et al.</i> 2014	40	Bilateral	16.75 ± 3.2	14.2 ± 2.8	12.5 ± 2.6	12.2 ± 1.6
Sunj <i>et al.</i> 2014a	49	Unilateral	—	—	—	—
	47	Bilateral	—	—	—	—
	96	Overall	14.8 ± 2.7	14.8 ± 4.8	—	21.07 ± 8.2
Rezk <i>et al.</i> 2016	52	Unilateral	19.1 ± 5.4	—	15.2 ± 3.3	18.6 ± 3.1
	53	Bilateral	18.9 ± 5.5	—	15.1 ± 3.2	16.4 ± 3.2
	105	Overall	18.9 ± 5.4	—	15.1 ± 3.1	17.4 ± 3.3